参考文献
1.Di Ciaula A, Wang DQ, Portincasa P. Gallbladder and gastric motility in obese newborns, pre-adolescents and adults. J Gastroenterol Hepatol, 2012, 27: 1298-1305.
2.Shabanzadeh DM, Sφrensen LT, Jφrgensen T. Determinants for gallstone formation-a new data cohort study and a systematic review with meta-analysis. Scand J Gastroenterol, 2016, 51 (10): 1239-1248.
3.Friedman GD. Natural history of asymptomatic and symptomatic gallstones. Am J Surg, 1993, 165 (4): 399-404.
4.Zhu L, AiliA, Zhang C, et al. Prevalence of and risk factors for gallstones in Uighur and Han Chinese. World J Gastroenterol, 2014, 20 (40): 14942-14949.
5.Smelt AH. Triglycerides and gallstone formation. Clin Chim Acta, 2010, 411 (21-22): 1625-1631.
6.Wang TY, Portincasa P, Liu M, et al. Mouse models of gallstone disease. CurrOpinGastroenterol, 2018, 34 (2):59-70.
7.Zhang FM, Chen LH, Chen HT, et al. Hepatitis C Virus Infection Is Positively Associated with Gallstones in Liver Cirrhosis. Digestion, 2016, 93 (3): 221-228.
8.Chiong C, Cox MR, Eslick GD. Gallstone disease is associated with rectal cancer: ameta-analysis. Scand J Gastroenterol, 2012, 47 (5): 553-564.
9.Lv J, Qi L, Yu C, et al. Gallstone Disease and the Risk of Ischemic Heart Disease. Arterioscler Thromb Vasc Biol, 2015, 35 (10): 2232-2237.
10.Chen Y, Kong J, Wu S. Cholesterol gallstone disease: focusing on the role of gallbladder. Lab Invest, 2015, 95 (2): 124.
11.刘京山.内镜微创保胆手术指南(2015版).中国内镜杂志,2016,22 (2): 113-114.
12.Portincasa P, Ciaula AD, Bonfrate L, et al. Therapy of gallstone disease: What it was, what it is, what it will be. World J Gastrointest Pharmacol Ther, 2012, 3 (2): 7-20.
13.Roma MG, Toledo FD, Boaglio AC, et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. ClinSci (Lond), 2011, 121 (12): 523-544.
14.Hou R, Goldberg AC. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acidsequestrants,andcombinations: comparative efficacy and safety. Endocrinol Metab Clin North Am, 2009, 38 (1): 79-97.
15.Zhu Y, Li F, Guo GL. Tissue-specific function of farnesoid X receptor in liver and intestine. Pharmacol Res, 2011, 63 (4): 259-265.
16.Sakorafas GH, Milingos D, Peros G. Asymptomatic cholelithiasis: ischolecystectomy really needed？Acritical reappraisal 15 years after the introduction of laparoscopic cholecystectomy. Dig Dis Sci, 2007, 52(5): 1313-1325.
17.Shabanzadeh DM, Sorensen LT, Jorgensen T. A Prediction Rule for Risk Stratification of Incidentally Discovered Gallstones: Results From a Large Cohort Study. Gastroenterology, 2016, 150 (1): 156-167.
18.Liew PL, Wang W, Lee YC, et al. Gallbladder disease among obese patients in Taiwan. Obes Surg, 2007, 17(3): 383.
19.Venneman NG, Besselink MG, Keulemans YC, et al. Ursode oxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. Hepatology, 2006, 43 (6): 1276-1283.
20.Brazzelli M, Cruickshank M, Kilonzo M, et al. Clinical effectiveness and cost-effectiveness of cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults presenting with uncomplicated symptomatic gallstones or cholecystitis: asystematic review and economic evaluation. Health Technol Assess, 2014, 18 (55): 1-101, v-vi.
21.Schöffmann T, Primavesi F, Stättner S, et al. Extracorporeal shock wave lithotripsy (ESWL) for the treatment of gallbladder stones: long-term results after more than 20 years. HPB, 2016, 18 (2): e855-e856.